Literature DB >> 10703931

Growth hormone treatment in adults with adult-onset growth hormone deficiency increases iliac crest trabecular bone turnover: a 1-year, double-blind, randomized, placebo-controlled study.

K Brixen1, T B Hansen, E Hauge, N Vahl, J O Jørgensen, J S Christiansen, L Mosekilde, C Hagen, F Melsen.   

Abstract

The effects of growth hormone (GH) substitution on bone metabolism were evaluated by dynamic histomorphometry on iliac crest bone biopsies. Twenty-nine patients, aged 21-61 years (mean 45.5 years), with adult-onset GH deficiency (GHD) were randomized to receive subcutaneous injections with GH (2 IU/m2/day = 0.67 mg/m2/day) or placebo for 12 months. Serum insulin-like growth factor I (IGF-I) levels increased 263 +/- 98% (mean +/- SD) during GH treatment (p < 0.0001). In the GH group, osteoid surface increased during treatment from 11% (3-15%) (median [25-75 percentiles]) to 21% (10-27%) (p = 0.01) and mineralizing surface from 4% (1-8%) to 11%(7-16%) (p = 0.04). Moreover, erosion surface tended to increase in the GH group from 2% (1-3%) to 4% (3-5%) (p = 0.07). The quiescent surface decreased in the GH group from 87% (83-96%) to 74% (68-87%) (p = 0.01). The adjusted appositional rate, mineral apposition rate, bone formation rate, bone erosion rate, mineralization lag time, and osteoid thickness remained unchanged during treatment. Erosion depth showed a trend toward increase in the GH group (p = 0.09), whereas wall thickness was unchanged. Bone balance at the remodeling unit level and activation frequency were unchanged. At the tissue level, bone erosion rate increased significantly from 26% (17-36%)/year to 39% (23-72%)/year (p = 0.03). Similarly, the bone formation rate at the tissue level tended to increase, from 24% (15-31%)/year to 36% (17%-63%)%/year (p = 0.06). Finally, bone balance at the tissue level decreased significantly from 1% (-2-2%)/year to -5% (-13-1%)/year (p = 0.01). No significant difference in change was seen in the cancellous bone volume. We conclude that 12 months of GH substitution therapy increases trabecular bone turnover. Moreover, our data suggest that bone balance at the bone multicellular unit level is not changed to positive.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10703931     DOI: 10.1359/jbmr.2000.15.2.293

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  5 in total

Review 1.  Long-term growth hormone replacement therapy in hypopituitary adults.

Authors:  Johan Verhelst; Roger Abs
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Growth hormone effects on cortical bone dimensions in young adults with childhood-onset growth hormone deficiency.

Authors:  L Hyldstrup; G S Conway; K Racz; A Keller; P Chanson; M Zacharin; A L Lysgaard; A H Andreasen; A-M Kappelgaard
Journal:  Osteoporos Int       Date:  2011-11-29       Impact factor: 4.507

3.  Trabecular bone score as a skeletal fragility index in acromegaly patients.

Authors:  A R Hong; J H Kim; S W Kim; S Y Kim; C S Shin
Journal:  Osteoporos Int       Date:  2015-10-07       Impact factor: 4.507

4.  Fracture risk is decreased in acromegaly--a potential beneficial effect of growth hormone.

Authors:  Peter Vestergaard; Leif Mosekilde
Journal:  Osteoporos Int       Date:  2003-11-19       Impact factor: 4.507

5.  The effect of two different GH dosages on final height and bone geometry.

Authors:  Fiorenzo Lupi; Mauro Bozzola; Silvia Longhi; Giovanni Farello; Giorgio Radetti
Journal:  Ital J Pediatr       Date:  2016-01-15       Impact factor: 2.638

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.